Shakeshaft, Amy
Panjwani, Naim
Collingwood, Amber
Crudgington, Holly
Hall, Anna
Andrade, Danielle M.
Beier, Christoph P.
Fong, Choong Yi
Gardella, Elena
Gesche, Joanna
Greenberg, David A.
Hamandi, Khalid
Koht, Jeanette
Lim, Kheng Seang
Møller, Rikke S.
Ng, Ching Ching
Orsini, Alessandro
Rees, Mark I.
Rubboli, Guido
Selmer, Kaja K.
Striano, Pasquale
Syvertsen, Marte
Thomas, Rhys H.
Zarubova, Jana
Richardson, Mark P.
Strug, Lisa J.
Pal, Deb K.
Funding for this research was provided by:
Sackler Institute for Translational Neurodevelopment, King's College London
Medical Research Council (MR/K013998/1)
Syddansk Universitet (17/18517)
Odense Universitetshospital
Nationwide Children's Hospital
Health and Care Research Wales
Helse Sør-Øst RHF (2016129, 2016129)
Epilepsy Research UK
Parc Geneteg Cymru
Abertawe Bro Morgannwg University NHS R&D
UCB
BioMarin Pharmaceutical
ENECTA
GW Pharmaceuticals
Kolfarma
Eisai
Norges Forskningsråd (299266)
NIHR Specialist Biomedical Research Centre for Mental Health of South London and Maudsley National Health Service Foundation Trust
Engineering and Physical Sciences Research Council (EP/N014391/1)
Medical Research Council, Centre for Neurodevelopmental Disorders (MR/N026063/1, MR/N026063/1)
Canadian Institutes of Health Research (201503MOP‐342469, 201503MOP‐342469)
Article History
Received: 27 August 2021
Accepted: 25 November 2021
First Online: 21 February 2022
Competing interests
: AS, NP, AC, HC, AH, CPB, CYF, EG, JG, DAG, KH, JK, KSL, RSM, CCN, AO, MIR, GR, JZ, MPR, LJS and DKP report no conflicts of interest. DA reports a grant and honoraria from Biocodex, honoraria from Eisai, royalties from UpToDate and grants from Ontario Brain Institute, McLaughlin Foundation and Dravet Syndrome Foundation, outside the present work. KKS reports a travel grant from UCB Nordic outside the present work. PS reports grants from Proveca and personal fees from Kolfarma, outside the present work. MS reports honoraria from Eisai. RHT reports honoraria from Sanofi, Eisai, GW Pharma, UCB Pharma, Zogenix, Arvelle and Bial and meeting support from LivaNova and Novartis outside the present work.